Celltech and American Cyanamid
Executive Summary
Lederle parent is Celltech's partner in a cancer research agreement. Lederle will shepherd through clinical trials, FDA review, and marketing any products developed by the British research firm. Celltech will receive $7.5 mil. initially for two years "to develop a new approach to antibody cancer imaging and therapy using" second generation "monoclonal antibodies," Celltech announced ("The Pink Sheet" April 14, In Brief).You may also be interested in...
Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
Health And Wellness Trademark Review 18 February, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit Delays NASH Data While It Confers With US FDA On Methodology
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: